产品
编 号：F351142
分子式：C6H10O5
分子量：162.14
分子式：C6H10O5
分子量：162.14
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 4084-27-9
产品详情
生物活性：
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes.
体内研究：
3-Deoxyglucosone (intragastric administration; 20 mg/kg; single dose)?impairs glucose tolerance with increased AUC, but the plasma glucagon levels are not significantly different. It developes impaired glucose regulation (IGR) with obviously pancreatic islet cell dysfunction in kunming mice and SD-rats.3-deoxyglucosone?(gastric gavage; 5-50 mg/kg; once daily; 2 weeks) is significantly increased in the upper small intestine (1.4-fold), lower small intestine (1.4-fold), ileum (1.4-fold) and colon (two fold) compared with the basal levels in the corresponding control group. In addition, the protein expressions of TAS1R2, TAS1R3 and TRPM5 in both duodenum and colon are significantly decreased.Animal Model:SD rats
Dosage:5, 20 and 50 mg/kg
Administration:oral administration; once daily; 2 weeks
Result:Was capable of accumulating in?intestinal?tissue?and thereby decreased?secretion?of?GLP-1?and insulin. ?
体外研究：
3-Deoxyglucosone (80 ng/ml-1000 ng/ml; 1 hour) markedly increases GLP-1 secretion by 1.23-folds in 300?ng/ml or 1000?ng/ml 3DG-treated group. But at alower concentration (80?ng/ml) has no effects.3-Deoxyglucosone (300 ng/ml; 1 hour) dramatically increases intracellular Ca2+ levels by Fluo-3/AM determination (2.5?μM for 30 mins). But 3DG does not affect intracellular cAMP levels in a cAMP Elisa assay.3-Deoxyglucosone (300 ng/ml; 1 hour) significantly increases the protein expression levels of TAS1R2, TAS1R3, and TRPM5 under both glucose-free and highconditions.
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes.
体内研究：
3-Deoxyglucosone (intragastric administration; 20 mg/kg; single dose)?impairs glucose tolerance with increased AUC, but the plasma glucagon levels are not significantly different. It developes impaired glucose regulation (IGR) with obviously pancreatic islet cell dysfunction in kunming mice and SD-rats.3-deoxyglucosone?(gastric gavage; 5-50 mg/kg; once daily; 2 weeks) is significantly increased in the upper small intestine (1.4-fold), lower small intestine (1.4-fold), ileum (1.4-fold) and colon (two fold) compared with the basal levels in the corresponding control group. In addition, the protein expressions of TAS1R2, TAS1R3 and TRPM5 in both duodenum and colon are significantly decreased.Animal Model:SD rats
Dosage:5, 20 and 50 mg/kg
Administration:oral administration; once daily; 2 weeks
Result:Was capable of accumulating in?intestinal?tissue?and thereby decreased?secretion?of?GLP-1?and insulin. ?
体外研究：
3-Deoxyglucosone (80 ng/ml-1000 ng/ml; 1 hour) markedly increases GLP-1 secretion by 1.23-folds in 300?ng/ml or 1000?ng/ml 3DG-treated group. But at alower concentration (80?ng/ml) has no effects.3-Deoxyglucosone (300 ng/ml; 1 hour) dramatically increases intracellular Ca2+ levels by Fluo-3/AM determination (2.5?μM for 30 mins). But 3DG does not affect intracellular cAMP levels in a cAMP Elisa assay.3-Deoxyglucosone (300 ng/ml; 1 hour) significantly increases the protein expression levels of TAS1R2, TAS1R3, and TRPM5 under both glucose-free and highconditions.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备